A 52-year-old woman with newly diagnosed ovarian cancer is being counseled about chemotherapy options. Her oncologist mentions several alkylating agents. All of the following alkylating agents are correctly paired with their primary mechanism of toxicity EXCEPT:

Explanation

## Alkylating Agent Toxicity Profiles ### Correct Toxicity Pairings (Options 0, 1, 2) **Option 0 — Cyclophosphamide & Hemorrhagic Cystitis:** **Key Point:** Cyclophosphamide is metabolized to acrolein, a highly toxic metabolite that concentrates in the bladder urine and causes hemorrhagic cystitis. This is a dose-limiting and potentially life-threatening toxicity. **Clinical Pearl:** Prevention involves aggressive hydration and frequent voiding to dilute and eliminate acrolein. Mesna (a uroprotective agent) is often co-administered to inactivate acrolein in the bladder. **High-Yield:** Hemorrhagic cystitis is the signature toxicity of cyclophosphamide — a must-know fact for NEET PG. **Option 1 — Melphalan & Myelosuppression:** **Key Point:** Melphalan is an oral alkylating agent that causes dose-limiting myelosuppression (bone marrow toxicity). Because of its predictable myelotoxicity, it is used in high-dose conditioning regimens for stem cell transplantation. **Option 2 — Busulfan & Organ Toxicity:** **Key Point:** Busulfan is notorious for causing: - **Pulmonary fibrosis** (busulfan lung) — can be irreversible and life-threatening - **Hepatic veno-occlusive disease (VOD)** — particularly at high doses used in conditioning - Myelosuppression **High-Yield:** Busulfan's pulmonary and hepatic toxicity is a classic NEET PG testable fact, especially in the context of stem cell transplantation conditioning. ### Incorrect Pairing (Option 3 — Cisplatin Toxicity Mechanism) **Warning:** This is the trap. The statement claims cisplatin's neuropathy and ototoxicity are caused by **"electrophilic alkylation of neuronal proteins."** This is **INCORRECT**. **Key Point:** Cisplatin's neurotoxicity (peripheral neuropathy) and ototoxicity are NOT mediated by alkylation. Instead, they result from: 1. **Accumulation in sensory neurons and inner ear cells** (high lipophilicity and poor clearance) 2. **Mitochondrial dysfunction** and oxidative stress 3. **Apoptosis of sensory neurons and cochlear hair cells** 4. **Platinum-DNA adduct formation** in non-dividing cells (not alkylation per se) The mechanism is **NOT electrophilic alkylation** — it is **platinum-mediated DNA damage and oxidative stress** in post-mitotic tissues. **Clinical Pearl:** Cisplatin's neuropathy is cumulative and dose-dependent. Patients often develop a characteristic stocking-glove sensory neuropathy that can be irreversible. Ototoxicity manifests as high-frequency hearing loss. ### Toxicity Comparison Table | Agent | Primary Toxicity | Mechanism | Prevention/Management | | --- | --- | --- | --- | | Cyclophosphamide | Hemorrhagic cystitis | Acrolein in bladder | Mesna, hydration, frequent voiding | | Melphalan | Myelosuppression | Bone marrow alkylation | Dose adjustment, stem cell support | | Busulfan | Pulmonary fibrosis, VOD | Alkylation + oxidative stress | Monitoring, dose reduction | | Cisplatin | Neuropathy, ototoxicity | Platinum accumulation + oxidative stress | Dose limitation, monitoring | **Mnemonic: ACME Toxicities** - **A**crolein → Cyclophosphamide (cystitis) - **C**umulative myelosuppression → Melphalan - **M**ultiple organs (lung, liver) → Busulfan - **E**ar & nerves → Cisplatin (but NOT by alkylation) [cite:KD Tripathi 8e Ch 62; Harrison 21e Ch 89]